Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors

Investigational New Drugs

Volumn 26, Issue 5, 2008, Pages 445-454

  Overman, Michael J ^a   Varadhachary, Gauri ^a   Kopetz, Scott ^a   Thomas, Melanie B ^a   Fukushima, Masakazu ^c   Kuwata, Keizo ^c   Mita, Akira ^c   Wolff, Robert A ^a   Hoff, Paulo M ^d   Xiong, Henry ^b   Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Center for Cancer and Blood Disorders   (United States)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

^d HOSPITAL SÍRIO LIBANÊS   (Brazil)

Author keywords

5 Flourouracil; Colorectal cancer; Phase 1; Solid tumor; TAS 102

Indexed keywords

5 CHLORO 6 (2 IMINOPYRROLIDIN 1 YL)METHYL 2,4(1H,3H) PYRIMIDINEDIONE; ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR; FLUOROURACIL; TAS 102; THYMIDINE PHOSPHORYLASE; THYMIDINE PHOSPHORYLASE INHIBITOR; TRIFLURIDINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DISTRIBUTION VOLUME; DOSE LIMITING TOXICITY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GRANULOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; OPTIMAL DRUG DOSE; PARAMETER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SOLID TUMOR; SYNCOPE; TASTE DISORDER; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TRIFLURIDINE; URACIL;

EID: 50349099053     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9142-3     Document Type: Article

References (21)

1. No authors listed (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 10(6):896-903
2. M Miwa 1998 Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 8 1274 1281
3. J Schuller 2000 Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Cancer Chemother Pharmacol 45 4 291 297
4. DB Longley DP Harkin PG Johnston 2003 5-fluorouracil: mechanisms of action and clinical strategies Nat Rev Cancer 3 5 330 338
5. T Emura 2004 A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells Int J Mol Med 13 4 545 549
6. OH Temmink 2005 Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells Anticancer Drugs 16 3 285 292
7. FJ Ansfield G Ramirez 1971 Phase I and II studies of 2¢-deoxy-5- (trifluoromethyl)-uridine (NSC-75520) Cancer Chemother Rep 55 2 205 208
8. Heidelberger C, Dexter DL, Wolberg WH (1970) Clinical pharmacology of 5-trifluoromethyl-2-deoxyuridine (F3TDR). Proc Am Assoc Cancer Res 35
9. T Emura 2005 Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo Int J Oncol 27 2 449 455
10. OH Temmink 2007 Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies Cancer Sci 98 6 779 789
11. J Ciccolini A Evrard P Cuq 2004 Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story Curr Med Chem Anticancer Agents 4 2 71 81
12. T Emura 2004 Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model Oncol Rep 11 2 381 387
13. T Emura 2004 A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA Int J Oncol 25 3 571 578
14. DS Hong 2006 Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors Cancer 107 6 1383 1390
15. S Sadahiro 2001 A pharmacological study of the weekday-on/weekend-off oral UFT schedule in colorectal cancer patients Cancer Chemother Pharmacol 47 5 457 460
16. S Sadahiro 1998 Preliminary study on the optimal dosage schedule for oral Tegafur/Uracil (UFT) chemotherapy International Journal of Clinical Oncology 3 7 12
17. AB Miller 1981 Reporting results of cancer treatment Cancer 47 1 207 214
18. Green MC, P.L., Theriault RL et al. (2006) Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC). 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24(18S):10576 (June 20 Supplement)
19. Wolff RA, H.P., Mita A, et al. (2006) A phase I trial of TAS-102 administered on a three times a day schedule in patients with solid tumors. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24(18S):2053 (June 20 Supplement)
20. OH Temmink 2006 Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells Cancer Chemother Pharmacol 57 2 171 179
21. T Emura 2004 An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA Int J Mol Med 13 2 249 255